Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 213-552-4 | CAS number: 976-70-5
Endpoint summary
Administrative data
Description of key information
Oral (Rat-Wistar, GLP, OECD TG423): LD50 >2000 mg/kg
(Schering AG, Report No: A03235; 2001-02-26)
Dermal (Rat-Wistar, GLP, OECD TG402): LD50 >2000 mg/kg
(Schering AG, Report No: A03234; 2001-02-26)
Additionally results of acute toxicity studies with aldona are cited in RTECS database (Feb 2010):
Intraperitoneal (rat); LD50: >700 mg/kg
(Journal of Pharmacology and Experimental Therapeutics. (Williams and Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- v. 126, p. 123, 1959 (JPETAB))
Intraperitoneal (rat); LD50: 490 mg/kg
(Journal of Pharmacology and Experimental Therapeutics. (Williams and Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- v. 126, p. 123, 1959 (JPETAB))
Key value for chemical safety assessment
Additional information
The single oral administration of ZK57564 to male and female Wistar rats (3/sex) at the dose of 2000 mg/kg resulted in transient rough hair coat, apathy, squatting position, decreased body temperature only in females. No compound-related macroscopic findings were seen. LD50 >2000 mg/kg [Schering AG, Report No: A03235; 2001-02-26]
Single dermal application of ZK 57564 to rats (3/sex) for 24 hours did not induce any clinical or pathological signs. LD50 >2000 mg/kg [Schering AG, Report No: A03234; 2001-02-26]
Additionally results of acute toxicity studies with aldona are cited in RTECS database (Feb 2010):
Intraperitoneal application of aldona to rats results in LD50: >700 mg/kg [Journal of Pharmacology and Experimental Therapeutics. (Williams and Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- v. 126, p. 123, 1959 (JPETAB)]
Single intraperitoneal application to rat lreas to an LD50: 490 mg/kg [Journal of Pharmacology and Experimental Therapeutics. (Williams and Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- v. 126, p. 123, 1959 (JPETAB)]
Justification for classification or non-classification
Based on the study results a classification according to Directive 67/548/EEC and Regulation (EC) 1272/2008 (CLP) is not required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
